StudyFinder

MT2025-06: Postmarketing, Prospective, Observational, Study to Assess and Characterize the Risk of Secondary Malignancies, and Long-term Safety Following Treatment with atidarsagene autotemcel (Lenmeldy )

Status: Recruiting

To assess and characterize the risk of malignancies, and long-term safety following treatment with atidarsagene autotemcel (Lenmeldy).

I'm interested

Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• live in the United States
• has been or will be treated for MLD with Lenmeldy
Conditions:

Rare Diseases

Keywords:

Metachromatic Leukodystrophy, MLD

Study Contact: Paul Orchard - orcha001@umn.edu
Principal Investigator: Paul Orchard
IRB Number: STUDY00025694

Back